Skin and its derivatives of hair follicles, nails, sweat, and oil glands play a myriad of important roles within our body. Since the skin comes into direct contact with the outside world, it is highly susceptible to cuts, abrasions, and burns. Although the skin has a higher regenerative capacity than most tissues, the repair of large-scale deep injuries, such as deep burns, is mainly scar repair. The current standard of care for patients with severe large area skin defects consists of autologous skin grafting or dermal substitutes. However, the shortage of donor skin sites and infection risks limit the application of grafts and emerging dermal substitutes still face challenges in delivering cells to clinically relevant wound topologies and the promotion of vascularization. The 3D bioprinting of skin models has garnered increasing research interest in recent years due to the potential in disease modeling, testing the efficacy of new treatments, and providing alternatives to animal testing. Continued developments in 3D bioprinting skin equivalents show promise in defining the composition of biomaterials, cells, and bioactive factors for accelerated wound regeneration.
In this webinar, we are fortunate to hear from a diverse panel of experts who will share with us their latest research & development, industry insights, and entrepreneurial activities. We will also have breakout rooms following the webinar for 30 minutes of networking. This serves to network freely and to connect Pitch3D start-ups and investors during the breakout session, you can apply here. The on-demand recording will also be available here after the event.
Dr Abbas Shafiee is a tissue engineering & regenerative medicine scientist interested in translational cell-based and tissue engineering strategies to treat human diseases.
Dr Shafiee completed his PhD at The University of Queensland on stem cell biology. His research career during his PhD had key contributions to delineating endothelial niche and vascular stem cells in the human placental tissues, including the seminal discovery of an entirely new stem cell population, coined as ‘Meso-Endothelial Bipotent Progenitor’ and the identification of key driver signatures for endothelial and bipotential progenitor function. Post-PhD, he joined Queensland University of Technology and conducted multiple projects on cancer and bone tissue engineering. Dr Shafiee has developed innovative tissue engineered models intersecting concepts from stem cell biology, cancer, and tissue engineering to study species-specific cancer bone metastasis at an unprecedented level of detail. Utilizing the tissue engineering concept, he was able to better understand the mechanisms of cancer bone metastasis. Additionally, he was successful in obtaining project grants, and developed a biomimetically designed scaffolds and investigated the interactions of multipotent mesenchymal stem/stromal cell and skin progenitors with 3D printed scaffolds.
Dr Shafiee joined Herston Biofabrication Institute (HBI, MNHHS, Brisbane) in 2020 and started a research program to develop, implement, and evaluate the applications of 3D printing, scanning, cell therapies, and biofabrication technologies in skin wound settings. Using 3D printing and stem/progenitor cell delivery he could develop new approaches to enhances physiological wound closure with reduced scar tissue formation. He is also is part of a national program aiming to develop 3D bioprinting technology to treat skin wounds.
Colin was the UK’s first Full Professor of Regenerative Medicine, before Founding CTIBIOTECH to create not only organ-based models for drug screening and efficacy testing, but also to create cell and organ therapies of the future. Coming from a background of Hematology / Oncology his work expanded in the 1990’s to stem cells and his academic group were first in the world to create neural and hepatic tissues from adult stem cells. Now at CTIBIOTECH they are leaders in 3D bioprinting models of the human body, with a lot of success in complex skin, tumors and liver systems.
Professor, University of Toronto
Dr. Guenther is a Full Professor in the Department of Mechanical and Industrial Engineering, with cross-appointment at the Institute of Biomedical Engineering at the University of Toronto. He obtained his doctoral degree from ETH Zurich and conducted postdoctoral research at the Massachusetts Institute of Technology. He received the ETH medal (2002), the Ontario Early Researcher Award (2009), the I.W. Smith Award of the Canadian Society of Mechanical Engineers (2010) and the Innovator of the Year (2013) and Safwat Zaky Research Leader (2021) Awards of the University of Toronto. He is interested in microfluidic and biofabrication strategies for hierarchical biomaterials and tissues. He invented several bioprinting technologies and currently serves as the founding Co-Director of the nationally unique Centre for Research and Applications in Fluidic Technologies (CRAFT), a collaborative research center between the University of Toronto and the National Research Council of Canada (NRC) that aims to accelerate the translation of microfluidic device innovations to industry and to the clinic.
Field Application Specialist at CELLINK
Amaris Castanon completed a Bachelor of Science at the University of Texas at El Paso (UTEP) in Cellular and Molecular Biochemistry and graduated with Magna Cum Laude high honors. She then completed a Master of Science with High Honors in Stem Cell and Regenerative Medicine at The University of Sheffield in the UK, while working at the Kroto Research Institute on a bioengineering project involving regenerative medicine approaches for peripheral nerve injury repair. Amaris has a strong international background having also completed studies abroad at Graz University of Technology in Austria, where she was enrolled in graduate bioengineering courses and discovered her strong passion for regenerative medicine. She has conducted an extensive amount of international research at institutions like University of Pennsylvania (UPENN), University of Texas Medical Branch (UTMB), Universidad Autonoma de Mexico (UNAM), Graz University of Technology (TU Graz), Fraunhofer Institute of Applied Optics and Precision and Engineering in Jena, University of Barcelona, and Kroto Research Institute. Her diverse background has allowed her to obtain significant experience in many research fields including those of stem cell culture, biomaterials, and biochemistry –all fields vital to the interfaced environment that 3D bioprinting faces today. Today, Amaris is a Field Application Specialist working with the Bioprinting team at CELLINK and is proud to form part of the BICO family, committed to revolutionize medicine through bioconvergence.
CEO and Founder of Poietis
Dr. Fabien GUILLEMOT is a scientist-turned-entrepreneur, CEO and Founder of Poietis, whose mission is to develop and market the Next-Gen Bioprinting platform to bring Tissue Engineering therapies to patients. Fabien has an over 20 years experience in the field of Biofabrication. He holds a PhD in Material Science (INSA, 2000) and an Habilitation in Health and Life Sciences (Bordeaux University, 2010). He was appointed Researcher at INSERM, France in 2005, and invited researcher at Harvard University in 2010. Bioprinting pioneer and inventor (with 100+ publications and 13 patents), he left for entrepreneurship via training at HEC-Paris.
William is a Ph.D. candidate within the School of Biomedical Engineering at the University of Melbourne. He obtained a certificate 3 in business management and an honors degree in medical biotechnology from the University of New South Wales where he first entered research focusing on biomaterials, stem cells, and nanofabrication processes for tissue regeneration. Currently, his Ph.D. investigates the use of acoustic micromanipulation and 3D bioprinting as tools to pattern and define the cellular microenvironment. William has held roles as a research assistant and a business development consultant, where he currently serves as a community and events manager for 3D Heals and an organizing committee member for the Australian Bioprinting Workshop.